NASDAQ •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 05/13/2026 10:35
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization15,198 mln
Float99.26 mln
Earnings Date08/04/2026
EPS
6.50
Strong
P / E
24.49
Premium valuation
Piotroski F-Score
6
/ 9
Solid
Beneish M-Score
-2.45
Borderline
1-Year Forecast
191
Attractive
Relative Strength
92
/ 100
Top performer
Business Description
Neurocrine Biosciences is a San Diego-based pharmaceutical company, founded in 1992, that researches and sells treatments for brain, hormonal, and immune-related conditions across the US and globally. Its marketed products address conditions such as tardive dyskinesia, Huntington's disease, endometriosis, uterine fibroids, and congenital adrenal hyperplasia. The company has a broad pipeline of experimental treatments targeting depression, schizophrenia, epilepsy, Alzheimer's disease, and obesity, among others. It also works alongside several major pharmaceutical partners, including AbbVie, Sanofi, and Takeda, through licensing and collaboration agreements.